METHODS OF TREATING CANCER SENSITIVE TO ANTI-EGFR THERAPY AND MODIFYING TREATMENT USING BLOOD BIOMARKERS

摘要

The present disclosure provides methods of treating cancer and modifying a cancer treatment for a cancer with an anti-EGFR drug by creating PRDX6 expression profiles and using the profiles to evaluate and optionally modify treatment. The present disclosure also provides assays and systems for assessing sensitivity of a cancer to an anti-EGFR therapy.

主权项

1. A method of treating cancer in a subject, the method comprising:
determining a pre-treatment level of peroxiredoxin 6 (PRDX6) protein in a sample taken from a subject having a cancer predicted to be sensitive to anti-epidermal growth factor receptor (EGFR) treatment; initiating a treatment regimen for the subject with an anti-EGFR drug, the treatment comprising administering one or more doses of the anti-EGFR drug to the subject over a period of time; determining a second level of PRDX6 in a second sample taken from the subject no later than about 4 weeks after the initial treatment with the anti-EGFR drug; creating a PRDX6 expression profile for the subject, wherein the PRDX6 expression profile compares the pre-treatment and second PRDX6 levels relative to the anti-EGFR treatment regimen; optionally determining one or more subsequent levels of PRDX6 in samples taken from the subject after the second sample; updating the PRDX6 expression profile for the subject to include any subsequent PRDX6 levels; using the PRDX6 expression profile to evaluate efficacy of the anti-EGRF drug in reducing tumor volume; and continuing, modifying, or discontinuing the treatment regimen with the anti-EGFR drug based on the PRDX6 expression profile.